Skip to content

Glycemic Effects of Honey

Glycemic Effects of Honey

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01371266
Enrollment
55
Registered
2011-06-10
Start date
2011-06-30
Completion date
2015-08-31
Last updated
2018-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-diabetes

Keywords

Glucose intolerance, Insulin resistance, Insulin, metabolic syndrome, honey, Inflammation, oxidative stress

Brief summary

Honey has been used as a sweetener for centuries. Recent data indicate that honey consumption may have beneficial effects upon glucose intolerance, a health issue currently affecting 57 million Americans of every age and ethnicity. In order to evaluate the glycemic effect of honey, the investigators will carry out a human trial assessing biomarkers of blood glucose responses, insulin sensitivity, oxidative stress, and inflammatory markers. Our primary objective is to determine the glycemic effects of honey in comparison to sucrose and high fructose corn syrup (HFCS). The investigators hypothesize that honey will promote improved glucose tolerance and insulin sensitivity compared to both sucrose and high fructose corn syrup in normal glycemic and glucose intolerant adults.

Detailed description

Glucose intolerance and insulin resistance are associated with the development of the metabolic syndrome and chronic diseases, including, hyperlipidemia, hypertension, obesity, and type II diabetes. Current National Institutes of Health statistics estimate that 1 in 6 Americans have insulin resistance (www.diabetes.niddk.nih.gov/dm/pubs/statistics). Insulin resistance in humans is associated with glucose intolerance, enhanced oxidative stress, inflammation and alterations in lipid profiles. Improvements in glucose tolerance are associated with improved insulin sensitivity resulting in improved inflammatory and oxidative status. Dietary modification to reduced day-long serum insulin concentration is postulated to decrease hepatic cholesterol production through inhibition of HMG CoA reductase, the rate limiting enzyme involved in cholesterol synthesis. Maintenance of normal blood glucose is dependent on the body's ability to modulate insulin secretion in response to the glucose load consumed. Although diet may be an important factor in glucose tolerance, the role of nutritive sweeteners has not been clearly defined. Much research has been performed on the effect of dietary sugars on chronic disease risk factors, including animal studies, and human studies ranging from epidemiologic to controlled feeding trials with most of this work focused on the monosaccharides: fructose and glucose or the disaccharide, sucrose. Little work has been done on the comparative effects of honey and other nutritive sweeteners in relation to glucose tolerance and insulin sensitivity.

Interventions

DIETARY_SUPPLEMENTHoney

60.7 grams orally daily times 14 days

DIETARY_SUPPLEMENTHigh Fructose Corn Syrup 55 (HFCS 55)

65.7 gram daily orally times 14 days

DIETARY_SUPPLEMENTCHO (sugar)

50 grams daily orally times 14 days

Sponsors

USDA Grand Forks Human Nutrition Research Center
Lead SponsorFED

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Men and women between 20-80 years of age. 2. Normal Glucose Tolerance * Fasting glucose between ≤105 mg/dl * Normal body weight or overweight (BMI 18-29.9) 3. Impaired Glucose Tolerance * Fasting glucose between 106-125 mg/dl * Overweight or obese (BMI 25 - 39.9) 4. Willingness to comply with the demands of the experimental protocol 5. Sedentary Lifestyle

Exclusion criteria

1. Known uncontrolled disease process 2. Diabetes mellitus 3. Use of medications that affect glucose metabolism 4. History of an eating disorder 5. Pregnancy or breast feeding 6. Inability to give consent 7. Unwillingness or inability to consume the supplemental sugars

Design outcomes

Primary

MeasureTime frameDescription
Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC15 weeksEvaluation of the effect of the treatment nutritive sweeteners on glucose tolerance.

Secondary

MeasureTime frameDescription
Insulin- 120 min OGTT - AUC15 weeksEvaluation of the effect of the treatment nutritive sweeteners on insulin sensitivity.
Triglycerides - 120 min OGTT - AUC15 weeksEvaluation of the effect of the treatment nutritive sweeteners on fat metabolism.
Inflammatory Markers15 weeksEffect of nutritive sweetener intake on systemic inflammation.
Oxidative Stress Markers15 weeksEffect of nutritive sweetener intake on systemic oxidative stress.
Serum Lipids15 weeksEffect of nutritive sweetener intake on lipid metabolism.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026